Takeda Pharmaceutical Company (TAK) has released an update.
Takeda Pharmaceutical reports mixed Phase 3 trial outcomes for its drug Soticlestat, with the SKYLINE study showing some positive secondary results in Dravet Syndrome despite missing the primary endpoint, and the SKYWAY study missing the primary endpoint for Lennox-Gastaut Syndrome. The drug was well-tolerated across both trials, and Takeda plans to discuss the comprehensive data with regulatory authorities to determine future steps.
For further insights into TAK stock, check out TipRanks’ Stock Analysis page.
